Both vendors used the four-day conference as an opportunity to provide key updates about their TAVR valves.

Early SVD has been reported in these devices, particularly three to four years after implantation. According to the FDA, this has resulted in surgical replacement procedures and transcatheter valve-in-valve interventions. In some cases, the patient died.

Monthly marijuana use, meanwhile, was not associated with a greater CAD risk. The full study is scheduled to be presented at ACC.23/WCC in New Orleans.

The new study, led by a team of Cleveland Clinic specialists, was published in Nature Medicine. 

As much as TAVR's popularity has grown in recent years, there are still many instances when a heart team may find that surgery offers the best path forward. 

Read our monthly recap of FDA-related news items from the world of cardiovascular medicine. 

Early evidence suggests the Electroducer Sleeve is safe and effective among patients presenting for certain interventional procedures. 

The study, to be presented March 5 at ACC.23/WCC in New Orleans, examined outcomes data from 1999 to 2020.